BFRI News and Press, Biofrontera Inc. From 05/24/22

WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Society 1 , indicating ...

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private placement with a single instit...

Biofrontera (NASDAQ:BFRI) has priced its $9.4M private offering of shares and warrants. The offering consists of 3,419,000 shares of common stock and warrants to purchase up to an aggregate of 3,419,000 shares of common stock. The purchase price for one share of common stock and a warrant to ...

WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in l...

Biofrontera, Inc. (BFRI) Q1 2022 Results Conference Call May 13, 2022 11:00 AM ET Company Participants Tirth Patel - LHA IR Hermann Lubbert - Executive Chairman Erica Monaco - CEO Presentation Operator Good morning and welcome to the Biofrontera Inc’s First Quarter 2022 Financial Resul...

Robinhood Markets (HOOD) +23% Bitcoin rebounds with rally above $30,000, but concerns remain. Endeavor Group Holdings (EDR) +20% on Q1 results. Molecular Partners (MOLN) +19% on Q1 results. Celularity (CELU) +18%. Coinbase Global (COIN) +14% Robinhood M...

Biofrontera press release (NASDAQ:BFRI): Q1 GAAP EPS of $0.32 beats by $0.48. Revenue of $9.8M (+106.3% Y/Y) misses by $0.03M. For further details see: Biofrontera GAAP EPS of $0.32 beats by $0.48, revenue of $9.8M misses by $0.03M

Conference call begins at 11 :0 0 a .m. Eastern time today WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical company specializing in the commercialization ...

WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. f...

Live Demonstration of New RhodoLED ® XL to be Featured WOBURN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced to...